205 related articles for article (PubMed ID: 28826843)
1. ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.
Balek L; Gudernova I; Vesela I; Hampl M; Oralova V; Kunova Bosakova M; Varecha M; Nemec P; Hall T; Abbadessa G; Hatch N; Buchtova M; Krejci P
Bone; 2017 Dec; 105():57-66. PubMed ID: 28826843
[TBL] [Abstract][Full Text] [Related]
2. Statins do not inhibit the FGFR signaling in chondrocytes.
Fafilek B; Hampl M; Ricankova N; Vesela I; Balek L; Kunova Bosakova M; Gudernova I; Varecha M; Buchtova M; Krejci P
Osteoarthritis Cartilage; 2017 Sep; 25(9):1522-1530. PubMed ID: 28583899
[TBL] [Abstract][Full Text] [Related]
3. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor and canonical WNT/β-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage.
Buchtova M; Oralova V; Aklian A; Masek J; Vesela I; Ouyang Z; Obadalova T; Konecna Z; Spoustova T; Pospisilova T; Matula P; Varecha M; Balek L; Gudernova I; Jelinkova I; Duran I; Cervenkova I; Murakami S; Kozubik A; Dvorak P; Bryja V; Krejci P
Biochim Biophys Acta; 2015 May; 1852(5):839-50. PubMed ID: 25558817
[TBL] [Abstract][Full Text] [Related]
5. [The molecular genetic background of hereditary craniosynostoses and chondrodysplasias].
Hertz JM; Juncker I; Christensen L; Østergaard JR; Jensen PK
Ugeskr Laeger; 2001 Sep; 163(36):4862-7. PubMed ID: 11571861
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
Wang Q; Green RP; Zhao G; Ornitz DM
Development; 2001 Oct; 128(19):3867-76. PubMed ID: 11585811
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
Hall TG; Yu Y; Eathiraj S; Wang Y; Savage RE; Lapierre JM; Schwartz B; Abbadessa G
PLoS One; 2016; 11(9):e0162594. PubMed ID: 27627808
[TBL] [Abstract][Full Text] [Related]
8. Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses.
Passos-Bueno MR; Sertié AL; Richieri-Costa A; Alonso LG; Zatz M; Alonso N; Brunoni D; Ribeiro SF
Am J Med Genet; 1998 Jul; 78(3):237-41. PubMed ID: 9677057
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.
Legeai-Mallet L; Benoist-Lasselin C; Munnich A; Bonaventure J
Bone; 2004 Jan; 34(1):26-36. PubMed ID: 14751560
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes.
Yan D; Chen D; Cool SM; van Wijnen AJ; Mikecz K; Murphy G; Im HJ
Arthritis Res Ther; 2011 Aug; 13(4):R130. PubMed ID: 21835001
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular bases of syndromic craniosynostoses.
Bonaventure J; El Ghouzzi V
Expert Rev Mol Med; 2003 Jan; 5(4):1-17. PubMed ID: 14987407
[TBL] [Abstract][Full Text] [Related]
13. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates SLC26A2-deficient chondrodysplasias.
Zheng C; Lin X; Xu X; Wang C; Zhou J; Gao B; Fan J; Lu W; Hu Y; Jie Q; Luo Z; Yang L
EBioMedicine; 2019 Feb; 40():695-709. PubMed ID: 30685387
[TBL] [Abstract][Full Text] [Related]
14. Genetic control of the cell proliferation-differentiation balance in the developing skull vault: roles of fibroblast growth factor receptor signalling pathways.
Morriss-Kay GM; Iseki S; Johnson D
Novartis Found Symp; 2001; 232():102-16; discussion 116-21. PubMed ID: 11277075
[TBL] [Abstract][Full Text] [Related]
15. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes.
Gudernova I; Vesela I; Balek L; Buchtova M; Dosedelova H; Kunova M; Pivnicka J; Jelinkova I; Roubalova L; Kozubik A; Krejci P
Hum Mol Genet; 2016 Jan; 25(1):9-23. PubMed ID: 26494904
[TBL] [Abstract][Full Text] [Related]
16. FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.
Karolak MR; Yang X; Elefteriou F
Hum Mol Genet; 2015 May; 24(9):2552-64. PubMed ID: 25616962
[TBL] [Abstract][Full Text] [Related]
17. An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.
Kimura T; Bosakova M; Nonaka Y; Hruba E; Yasuda K; Futakawa S; Kubota T; Fafilek B; Gregor T; Abraham SP; Gomolkova R; Belaskova S; Pesl M; Csukasi F; Duran I; Fujiwara M; Kavkova M; Zikmund T; Kaiser J; Buchtova M; Krakow D; Nakamura Y; Ozono K; Krejci P
Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952673
[TBL] [Abstract][Full Text] [Related]
18. New insight on FGFR3-related chondrodysplasias molecular physiopathology revealed by human chondrocyte gene expression profiling.
Schibler L; Gibbs L; Benoist-Lasselin C; Decraene C; Martinovic J; Loget P; Delezoide AL; Gonzales M; Munnich A; Jais JP; Legeai-Mallet L
PLoS One; 2009 Oct; 4(10):e7633. PubMed ID: 19898608
[TBL] [Abstract][Full Text] [Related]
19. Thyroid hormones regulate fibroblast growth factor receptor signaling during chondrogenesis.
Barnard JC; Williams AJ; Rabier B; Chassande O; Samarut J; Cheng SY; Bassett JH; Williams GR
Endocrinology; 2005 Dec; 146(12):5568-80. PubMed ID: 16150908
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yu Y; Hall T; Eathiraj S; Wick MJ; Schwartz B; Abbadessa G
Anticancer Drugs; 2017 Jun; 28(5):503-513. PubMed ID: 28240679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
